Patents Assigned to Sigmoid Pharma Limited
-
Publication number: 20180360909Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa, Monica Rosa
-
Publication number: 20180264076Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.Type: ApplicationFiled: May 22, 2018Publication date: September 20, 2018Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
-
Publication number: 20180243210Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.Type: ApplicationFiled: May 1, 2018Publication date: August 30, 2018Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa
-
Publication number: 20180228866Abstract: The present invention relates to a formulation comprising an inhibitor of NFAT activation for use in treating or preventing undesirable effects, more particularly undesirable effects occurring in conjunction with T cell-mediated therapies. The undesirable effects may be cytokine release syndrome (CRS) or symptoms associated with gastrointestinal (GI) inflammation, for example associated with inflammatory bowel diseases, such as ulcerative colitis, optionally caused by activated T cell activity. In addition to ameliorating undesirable effects, the invention is aimed at also maintaining the therapeutic effects of the T-cell mediated therapy.Type: ApplicationFiled: August 12, 2016Publication date: August 16, 2018Applicant: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 9999651Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.Type: GrantFiled: January 29, 2016Date of Patent: June 19, 2018Assignee: Sigmoid Pharma LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
-
Publication number: 20180147254Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: November 6, 2015Publication date: May 31, 2018Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa, Mónica Torres Rosa, Dáire O'Donnell, Wyatt Renaud of Calhane
-
Patent number: 9980902Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.Type: GrantFiled: April 4, 2016Date of Patent: May 29, 2018Assignee: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa
-
Patent number: 9950051Abstract: This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.Type: GrantFiled: October 27, 2015Date of Patent: April 24, 2018Assignee: Sigmoid Pharma LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Monica Torres Rosa
-
Publication number: 20180071387Abstract: A pharmaceutical composition comprising a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising at least one immunomodulator selected from an adjuvant, an antigen or a combination thereof. A method of manufacturing shaped compositions comprises mixing an aqueous solution of a water-soluble polymer with an oil-based liquid to form a water-in-oil emulsion, at least one of the aqueous solution and the oil-based liquid comprising an antigen or an adjuvant or a combination thereof, and then causing or allowing the resultant suspension to solidify into one or more beads or other shaped elements.Type: ApplicationFiled: November 15, 2017Publication date: March 15, 2018Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Mónica Torres Rosa, Edward Charles Lavelle
-
Publication number: 20180042989Abstract: Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.Type: ApplicationFiled: October 23, 2017Publication date: February 15, 2018Applicant: Sigmoid Pharma LimitedInventors: Vincenzo Aversa, Ivan Coulter, Mónica Torres Rosa, Bernard Francis McDonald
-
Patent number: 9878036Abstract: A pharmaceutical composition comprising a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising at least one immunomodulator selected from an adjuvant, an antigen or a combination thereof. A method of manufacturing shaped compositions comprises mixing an aqueous solution of a water-soluble polymer with an oil-based liquid to form a water-in-oil emulsion, at least one of the aqueous solution and the oil-based liquid comprising an antigen or an adjuvant or a combination thereof, and then causing or allowing the resultant suspension to solidify into one or more beads or other shaped elements.Type: GrantFiled: August 12, 2010Date of Patent: January 30, 2018Assignee: Sigmoid Pharma LimitedInventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Monica Torres Rosa, Edward Charles Lavelle
-
Patent number: 9844513Abstract: The present application provides a method for treating or preventing Celiac disease. In one embodiment the method comprises administering to a patient in need thereof a composition comprising minicapsules, wherein the minicapsules comprise a steroid in a liquid, semi-solid or solid core, the minicapsules having release profiles to release the steroid in an active form at one or more sites along the gastrointestinal tract, the one or more sites comprising the proximal small intestine beginning at the duodenum and ending at the ileum. In a related embodiment the method comprises administering budesonide to a patient in need thereof in a pre-solubilized drug delivery format.Type: GrantFiled: April 6, 2012Date of Patent: December 19, 2017Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 9821024Abstract: Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.Type: GrantFiled: November 25, 2011Date of Patent: November 21, 2017Assignee: Sigmoid Pharma LimitedInventors: Vincenzo Aversa, Ivan Coulter, Mónica Torres Rosa, Bernard Francis McDonald
-
Publication number: 20170246242Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.Type: ApplicationFiled: May 16, 2017Publication date: August 31, 2017Applicant: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Publication number: 20170196934Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency.Type: ApplicationFiled: January 19, 2017Publication date: July 13, 2017Applicant: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 9675558Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.Type: GrantFiled: February 23, 2016Date of Patent: June 13, 2017Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Patent number: 9585844Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic or prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.Type: GrantFiled: June 29, 2015Date of Patent: March 7, 2017Assignee: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Publication number: 20160324919Abstract: An oral modified release composition comprising cyclosporin, wherein the composition is for use in the treatment of ulcerative colitis in a patient, wherein the composition is for use in the concurrent treatment of the patient with an active agent selected from an aminosalicylate and a steroid, and a fixed or free combination thereof. Also claimed are kits comprising the oral modified release composition and the active agent. Also disclosed are methods for the treatment of ulcerative colitis using the oral modified release composition.Type: ApplicationFiled: January 12, 2015Publication date: November 10, 2016Applicant: Sigmoid Pharma LimitedInventor: Ivan Coulter
-
Publication number: 20160317609Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.Type: ApplicationFiled: November 7, 2014Publication date: November 3, 2016Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa, Monica Rosa
-
Publication number: 20160310561Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: November 7, 2014Publication date: October 27, 2016Applicant: Sigmoid Pharma LimitedInventors: Ivan Coulter, Vincenzo Aversa, Bernard Francis McDonald, Monica Rosa